PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans

Diabetologia

Volumn 57, Issue 10, 2014, Pages 2103-2107

  Peter, Andreas ^a,b   Kovarova, Marketa ^a,c   Nadalin, Silvio ^a   Cermak, Tomas ^c   Königsrainer, Alfred ^a   Machicao, Fausto ^a,b   Stefan, Norbert ^a,b   Häring, Hans Ulrich ^a,b   Schleicher, Erwin ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^c UNIVERSITY OF PARDUBICE   (Czech Republic)

Author keywords

Diabetes mellitus; Fatty acids; Fatty liver; Hepatic lipid fractions; Insulin resistance; NAFL; Obesity; PNPLA3I148M gene variant; PUFA; Triacylglycerol; Linolenic acid

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; ARACHIDIC ACID; ARACHIDONIC ACID; CHOLESTEROL ESTER; DOCOSAPENTAENOIC ACID; FATTY ACID SYNTHASE; ICOSATRIENOIC ACID; LIGNOCERIC ACID; LINOLEIC ACID; LINOLENIC ACID; MESSENGER RNA; OLEIC ACID; OMEGA 3 FATTY ACID; PALMITIC ACID; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING PROTEIN 3; PHOSPHOLIPASE; PHOSPHOLIPID; SATURATED FATTY ACID; STEARIC ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; UNCLASSIFIED DRUG; ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNSATURATED FATTY ACID;

ALLELE; ARTICLE; ENZYME SPECIFICITY; FAT CONTENT; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIPID COMPOSITION; LIPID LIVER LEVEL; LIPOGENESIS; LIVER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; GENETICS; LIPID METABOLISM; METABOLISM; PHYSIOLOGY;

FATTY ACIDS, UNSATURATED; GENOTYPE; HUMANS; LINOLENIC ACIDS; LIPASE; LIPID METABOLISM; LIVER; MEMBRANE PROTEINS; TRIGLYCERIDES;

EID: 84926660045     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3310-0     Document Type: Article

References (10)

1. Cohen JC, Horton JD, Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332:1519–1523
2. Romeo S, Kozlitina J, Xing C et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465
3. Kantartzis K, Thamer C, Peter A et al (2009) High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 58:1281–1288
4. Liu YL, Patman GL, Leathart JB et al (2014) Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. doi:10.1016/j.jhep.2014.02.030
5. Kumari M, Schoiswohl G, Chitraju C et al (2012) Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltrans-ferase. Cell Metab 15:691–702
6. Li JZ, Huang Y, Karaman R et al (2012) Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest 122:4130–4144
7. Ruhanen H, Perttilä J, Hölttä-Vuori M et al (2014) PNPLA3 mediates hepatocyte triacylglycerol remodeling. J Lipid Res 55:739–746
8. Perttila J, Huaman-Samanez C, Caron S et al (2007) PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. Am J Physiol Endocrinol Metab 302:E1063–E1069
9. Puri P, Baillie RA, Wiest MM et al (2007) A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46: 1081–1090
10. El Badry AM, Graf R, Clavien PA (2007) Omega 3—Omega 6: what is right for the liver? J Hepatol 47:718–725